Skip to main content

TQT Study

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Spero Therapeutics
Spero TherapeuticsMA - Cambridge
1 program
1
Tebipenem Pivoxil HydrobromidePhase 11 trial
Active Trials
NCT04238195Completed24Est. Feb 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Spero TherapeuticsTebipenem Pivoxil Hydrobromide

Clinical Trials (1)

Total enrollment: 24 patients across 1 trials

NCT04238195Spero TherapeuticsTebipenem Pivoxil Hydrobromide

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

Start: Jan 2020Est. completion: Feb 202024 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.